FDA Clears Low-Dose MRI Contrast Agent Vueway for Newborns and Infants

Key Takeaways

• FDA expands Vueway use to newborns and infants.
• Half‑dose gadopiclenol matches image quality of full‑dose agents.
• No new safety signals observed in neonate clinical trials.
• Over 3.5 M doses already used across ~900 US sites.

Pulse Analysis

Pediatric magnetic resonance imaging has long wrestled with the trade‑off between diagnostic clarity and gadolinium exposure. Neonates and infants possess developing blood‑brain barriers, making them especially susceptible to potential long‑term retention of gadolinium‑based contrast agents (GBCAs). Radiology societies therefore advocate for the lowest effective dose, yet historically few agents were cleared for use below two years of age, leaving a safety gap in early‑life imaging protocols.

Vueway’s active ingredient, gadopiclenol, leverages a macrocyclic structure and high relaxivity to achieve comparable signal enhancement at 0.05 mmol/kg—roughly half the dose required by conventional agents such as gadobutrol. In pivotal trials, infants under two years received the reduced dose without loss of lesion detectability, and the safety profile remained consistent with adult data, showing no new adverse events. The FDA’s decision reflects confidence in the agent’s pharmacokinetics and its ability to meet rigorous pediatric imaging standards while curbing cumulative gadolinium load.

The market impact is immediate. With over 3.5 million doses already distributed across 900 U.S. facilities, Bracco is positioned to capture hospitals seeking dose‑sparing solutions amid growing regulatory scrutiny of linear GBCAs. Competitors like Bayer’s gadobutrol and Guerbet’s gadoterate meglumine will need to emphasize safety data or develop similar low‑dose formulations to stay competitive. As imaging centers prioritize long‑term patient safety, Vueway’s expanded label may accelerate adoption of macrocyclic, low‑dose GBCAs and reshape procurement strategies across the radiology ecosystem.